Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11696738 | 0.80 | MAPT (0.71) | EGFRNOS1NOS2CYP1A2CYP3A4 | |
| SCHEMBL10798830 | 0.80 | TAAR1 (0.53) | TAAR1NOS1NOS2CYP1A2CYP3A4 | |
| SCHEMBL2085942 | 0.79 | GAA (0.51) | EGFRTAAR1DRD4DRD3CYP1A2 | |
| SCHEMBL25522787 | 0.79 | NOS1 (0.45) | NOS1NOS2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2460900 | 0.79 | CYP2C19 (0.48) | DRD3NOS1NOS2CYP1A2CYP3A4 | |
| SCHEMBL9827188 | 0.79 | CHRNB2 (0.47) | NOS1NOS2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4663442 | 0.79 | NOS1 (0.51) | NOS1NOS2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11674690 | 0.77 | DRD4 (0.47) | EGFRTAAR1DRD4DRD3CYP1A2 | |
| SCHEMBL171395 | 0.77 | ALDH1A1 (0.56) | TAAR1NOS1NOS2MAPTCYP2C19 | |
| SCHEMBL11661296 | 0.76 | F2R (0.54) | EGFRDRD4DRD3CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9527846-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-12-27 | — | — | US | disclosed |
| EP-2788349-B1 | KINASE INHIBITORS | CHIESI FARMA SPA (IT) | 2016-10-26 | — | — | EP | disclosed |
| US-20160229852-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-08-11 | — | — | US | disclosed |
| US-9315503-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-04-19 | — | — | US | disclosed |
| US-20150344475-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-03 | — | — | US | disclosed |
| US-9145413-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-09-29 | — | — | US | disclosed |
| US-9139584-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-09-22 | — | — | US | disclosed |
| US-20150080375-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-03-19 | — | — | US | disclosed |
| US-8907094-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-12-09 | — | — | US | disclosed |
| US-20140323470-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-10-30 | — | — | US | disclosed |
| EP-2788349-A1 | KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2014-10-15 | — | — | EP | disclosed |
| WO-2013083604-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-13 | — | — | WO | disclosed |
| US-20130150343-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344475-A1 | KINASE INHIBITORS | MAPK1, MAP3K1, MAPK6 | EGFR 974/4885TAAR1 897/4885DRD4 4842/4885 |
| US-20160229852-A1 | KINASE INHIBITORS | MAPK1, MAP3K1, MAPK6 | EGFR 974/4885TAAR1 897/4885DRD4 4842/4885 |
| US-20150080375-A1 | KINASE INHIBITORS | MAPK1, MAP3K1, MAPK6 | EGFR 974/4885TAAR1 897/4885DRD4 4842/4885 |
| US-20140323470-A1 | KINASE INHIBITORS | MAPK1, MAP3K1, MAPK6 | EGFR 974/4885TAAR1 897/4885DRD4 4842/4885 |
| US-20130150343-A1 | KINASE INHIBITORS | MAPK1, MAP3K1, MAPK6 | EGFR 974/4885TAAR1 897/4885DRD4 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.